정신신체의학 (Korean Journal of Psychosomatic Medicine)

한국정신신체의학회 (Korean Psychosomatic Society)
권호 표지
DOI QR코드

DOI QR Code

항정신병약물 사용과 연관된 체중 증가와 비만의 관리

Management of Weight Gain and Obesity Associated With Antipsychotics

  • 이나현 (건양대학교병원 정신건강의학과) ;
  • 이재창 (계요의료재단 계요병원 정신건강의학과)
  • Lee, Na-Hyun (Department of Psychiatry, Konyang University Hospital) ;
  • Lee, Jae-Chang (Department of Psychiatry, Keyo Hospital, Keyo Medical Foundation)
  • 투고 : 2021.11.04
  • 심사 : 2021.11.23
  • 발행 : 2021.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

연구목적 항정신병약물 사용시 체중 증가 위험이 높고, 정신질환자의 비만 유병률도 높다. 비만은 다양한 합병증을 유발하고 치료 순응도와 삶의 질을 저하시키기 때문에 정신질환자의 비만 관리는 중요하다. 방 법 본 종설에서는 학술 검색을 통하여 항정신병약물 사용시 발생할 수 있는 비만의 관리 전략에 대해 정리해 보았다. 결 과 치료 초기부터 비만관련 위험 요인과 관련 지표(체중, 체질량지수, 허리둘레,공복혈당 및 공복지질, 혈압)에 대해 평가하고, 정기적인 모니터링을 시행한다. 항정신병약물을 사용하며 비만이 유발된 경우 대사성 위험이 적은 약제로 변경을 시도할 수 있다. 환자 및 가족에서 비만 관리 필요성과 식이 및 운동 조절 등에 대한 충분한 안내도 필요하다. 비약물적 치료를 통해 적절한 체중 감량이 이뤄지지 않는 경우 항비만약물들의 사용도 고려할 수 있다. 결 론 항정신병약물 사용시 유발되는 체중 증가와 비만 관리를 위하여 비약물적, 약물적 요법을 적용할 수 있다. 항비만약물을 사용할 경우에는 정신질환의 특성, 약물의 안정성, 약물 상호작용을 고려해야 한다.

Objectives : The risk of weight gain is high when using antipsychotic drugs, and the prevalence of obesity in people with mental illness is high. Obesity management in psychiatric patients is important because obesity causes various complications and lowers treatment adherence and quality of life. Methods : In this review, we summarized the management strategies for obesity that can occur when using antipsychotic drugs through a web search. Results : Evaluate obesity-related risk factors and related indicators from the beginning of treatment, and conduct regular monitoring. If an antipsychotic drug is used and obesity is induced, a change to a drug with a low metabolic risk may be attempted. Sufficient interventions are also needed on the need to manage obesity, a healthy diet, and exercises in patients and their families. If weight loss is not achieved and obesity-related complications are associated, the use of anti-obesity drugs may be considered. Pharmacological treatment approaches should be carefully considered. Conclusions : Non-pharmacological and pharmacological therapies can be applied to manage weight gain and obesity caused by the use of antipsychotic drugs. When using anti-obesity drugs, the characteristics of mental disorders, drug safety, and drug interactions should be considered.

키워드

참고문헌

  1. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-2600. https://doi.org/10.1210/jc.2004-0372
  2. Hill AJ. Psychological aspects of obesity. Psychiatry 2005;4:26-30. https://doi.org/10.1383/psyt.4.4.26.63443
  3. Compton MT, Daumit GL, Druss BG. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harv Rev Psychiatry 2006;14:212-222. https://doi.org/10.1080/10673220600889256
  4. Kolotkin RL, Corey-Lisle PK, Crosby RD, Swanson JM, Tuomari AV, L'Italien GJ. Mitchell JE. Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. Obesity 2008;16:749-754. https://doi.org/10.1038/oby.2007.133
  5. Naughton M, Dinan TG, Scott LV. Corticotropin-releasing hormone and the hypothalamic-pituitary-adrenal axis in psychiatric disease. Vol. 124. 1st ed. Elsevier B.V.; 2014.
  6. Menard C, Pfau ML, Hodes GE, Russo SJ. Immune and neuroendocrine mechanisms of stress vulnerability and resilience. Neuropsychopharmacology 2017;42:62-80. https://doi.org/10.1038/npp.2016.90
  7. Zhou X, Keitner GI, Qin B, Ravindran AV, Bauer M, Del Giovane C, Zhao J, Liu Y, Fang Y, Zhang Y, Xie P. Atypical Antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. Int J Neuropsychopharmacol 2015;18:pyv060. https://doi.org/10.1093/ijnp/pyv060
  8. Driessen J, Baik SH, Zhang Y. Trends in off-label use of second-generation antipsychotics in the medicare population from 2006 to 2012. Psychiatr Serv 2016;67:898-903. https://doi.org/10.1176/appi.ps.201500316
  9. Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: Management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat 2017;13:2231-2241. https://doi.org/10.2147/NDT.S113099
  10. Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab 2014;25:593-600. https://doi.org/10.1016/j.tem.2014.07.004
  11. Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 2003;75:255-260. https://doi.org/10.1016/S0091-3057(03)00079-0
  12. Lu ML, Wang TN, Lin TY, Shao WC, Chang SH, Chou JY, Ho YF, Liao YT, Chen VCH. Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin. Prog Neuropsychopharmacol Biol Psychiatry 2015; 58:47-50. https://doi.org/10.1016/j.pnpbp.2014.12.001
  13. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66:51-57. https://doi.org/10.1016/S0920-9964(02)00498-X
  14. De Hert M, Detraux J, Van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012;8:114-126. https://doi.org/10.1038/nrendo.2011.156
  15. Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008;105:175-187. https://doi.org/10.1016/j.schres.2008.07.006
  16. Moon SJ, Kim KH, Song JY, Paik J. The Causes of Death of the Institutionalized Population of Kkottongnae: Comparison between Severe Mental Illness Group (SMI) and Non-Severe Mental Illness Group (Non-SMI), Korean J Biol Psychiatry 2009;16:198-204.
  17. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, Maj M, McIntyre RS, Naber D, Newcomer JW, Olfson M, Osby U, Sartorius N, Lieberman JA. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 2008;514-519.
  18. Bak M, Fransen A, Janssen J, Van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 2014;9:10-12.
  19. Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med 2010;40:187-200. https://doi.org/10.1017/s0033291709990407
  20. Vandenberghe F, Gholam-Rezaee M, Saigi-Morgui N, Delacretaz A, Choong E, Solida-Tozzi A, Kolly S, Thonney J, Gallo SF, Hedjal A, Ambresin AE, von Gunten A, Conus P, Eap CB. Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry 2015;76:e1417-e1423. https://doi.org/10.4088/jcp.14m09358
  21. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-1773. https://doi.org/10.1001/jama.2009.1549
  22. Hoffmann VP, Case M, Stauffer VL, Jacobson JG, Conley RR. Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, control. J Clin Psychopharmacol 2010;30:656-660. https://doi.org/10.1097/JCP.0b013e3181faf670
  23. Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf 2015;14:73-96. https://doi.org/10.1517/14740338.2015.974549
  24. Baptista T, Kin NMKNY, Beaulieu S, De Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002;35:205-219. https://doi.org/10.1055/s-2002-36391
  25. Prevalence of Obesity and Incidence of Obesity-Related Comorbidities in Koreans Based on National Health Insurance Service Health Checkup Data 2006-2015 (J Obes Metab Syndr 2018;27:46-52). Vol. 27. 2020.
  26. Citrome L, Volavka J. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care 2004;27.
  27. Vandenberghe F, Najar-Giroud A, Holzer L, Conus P, Eap CB, Ambresin AE. Second-generation antipsychotics in adolescent psychiatric patients: metabolic effects and impact of an early weight change to predict longer term weight gain. J Child Adolesc Psychopharmacol 2018;28:258-265. https://doi.org/10.1089/cap.2017.0038
  28. Hasnain M, Vieweg WVR, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med 2012;124:154-167. https://doi.org/10.3810/pgm.2012.07.2577
  29. Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, Kushner RF, Daniels SR, Wadden TA, Tsai AG, Hu FB, Jakicic JM, Ryan DH, Wolfe BM, Inge TH. The science of obesity management: an endocrine society scientific statement. Endocr Rev 2018;39:79-132. https://doi.org/10.1210/er.2017-00253
  30. Foster GD, Wadden TA, Vogt RA, Brewer G. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997;65; 79-85. https://doi.org/10.1037/0022-006X.65.1.79
  31. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014;63:2985-3023. https://doi.org/10.1016/j.jacc.2013.11.004
  32. Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, Wang Z, Elraiyah T, Brito JP, Mauck KF, Lababidi MH, Prokop LJ, Asi N, Wei J, Fidahussein S, Montori VM, Murad MH. Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015;100:363-370. https://doi.org/10.1210/jc.2014-3421
  33. Balf G, Stewart TD, Whitehead R, Baker RA. Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective. Prim Care Companion J Clin Psychiatry 2008;10:15-24. https://doi.org/10.4088/PCC.v10n0104
  34. Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo ALC, Martinotti G, Mazza M, Perna G, Carano A, De Bartolomeis A, Di Giannantonio M, De Berardis D. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf 2016;15:1329-1347. https://doi.org/10.1080/14740338.2016.1201475
  35. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005;27:1930-1941. https://doi.org/10.1016/j.clinthera.2005.12.005
  36. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003; 23:595-600. https://doi.org/10.1097/01.jcp.0000095347.32154.08
  37. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 2012;140:159-168. https://doi.org/10.1016/j.schres.2012.03.017
  38. Bonfioli E, Berti L, Goss C, Muraro F, Burti L. Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials. BMC Psychiatry 2012;12:78. https://doi.org/10.1186/1471-244x-12-78
  39. Hasnain M, Vieweg WVR. Do we truly appreciate how difficult it is for patients with schizophrenia to adapt a healthy lifestyle? Acta Psychiatr Scand 2011;409-410.
  40. Grimm JJ. Interaction of physical activity and diet: implications for insulin- glucose dynamics. Public Health Nutr 1999;2: 363-368. https://doi.org/10.1017/S136898009900049X
  41. Stanhope KL, Havel PJ. Fructose consumption: recent results and their potential implications. Ann New York Acad Sci 2010;15-24.
  42. de Ruyter JC, Olthof MR, Seidell JC, Katan MB. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med 2012;367:1397-1406. https://doi.org/10.1056/NEJMoa1203034
  43. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350. https://doi.org/10.1056/NEJM200105033441801
  44. Turk Y, Theel W, Kasteleyn MJ, Franssen FME, Hiemstra PS, Rudolphus A, Taube C, Braunstahl GJ. High intensity training in obesity: a Meta-analysis. Obes Sci Pract 2017;3:258-271. https://doi.org/10.1002/osp4.109
  45. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007;1-163.
  46. Gierisch JM, Nieuwsma JA, Bradford DW, Wilder CM, Mann-Wrobel MC, McBroom AJ, Wing L, Musty MD, Chobot MM, Hasselblad V, Williams JW Jr. Interventions to improve cardiovascular risk factors in people with serious mental illness. Duke Evidence-based Practice Center: Agency for Healthcare Research and Quality (US), Rockville (MD);2013.
  47. Yarborough BJH, Leo MC, Stumbo S, Perrin NA, Green CA. STRIDE: a randomized trial of a lifestyle intervention to promote weight loss among individuals taking antipsychotic medications. BMC Psychiatry 2013;13:1-11. https://doi.org/10.1186/1471-244x-13-1
  48. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008;193:101-107. https://doi.org/10.1192/bjp.bp.107.042853
  49. Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 2003;108:324-332. https://doi.org/10.1034/j.1600-0447.2003.00218.x
  50. Loh C, Meyer J, Leckband S. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry 2006;18:23-31.
  51. Bruins J, Jorg F, Bruggeman R, Slooff C, Corpeleijn E, Pijnenborg M. The effects of lifestyle interventions on (longterm) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a metaanalysis. PLoS One 2014;9:1-20.
  52. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, Perez-Iglesias R, Martinez-Garcia O, Perez-Pardal T, Ramirez-Bonilla ML, Crespo-Facorro B. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006;67:1253-1260. https://doi.org/10.4088/JCP.v67n0812
  53. Korean Society for the Study of Obesity. Guideline for the management of obesity;2020. p.97.
  54. Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. Vasc Health Risk Manag 2007;3;817-821.
  55. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. Br Med J 2007;335:1194-1199.
  56. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 2004;27: 155-161. https://doi.org/10.2337/diacare.27.1.155
  57. Werneke U, Taylor D, Sanders TAB. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol 2002;17:145-160. https://doi.org/10.1097/00004850-200207000-00001
  58. Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med 2018;130:173-182. https://doi.org/10.1080/00325481.2018.1435129
  59. Dossabhoy NR, McRight S, Sangha B, Khan S, Adgeh C. Orlistat-induced oxalate nephropathy may be dose-independent and present as a late manifestation. J Louisiana State Med Soc Off Organ Louisiana State Med Soc 2013;165:283-285.
  60. Buysschaert B, Aydin S, Morelle J, Hermans MP, Jadoul M, Demoulin N. Weight loss at a high cost: orlistat-induced late-onset severe kidney disease. Diabetes Metab 2016;42: 62-64. https://doi.org/10.1016/j.diabet.2015.08.006
  61. Weir MA, Beyea MM, Gomes T, Juurlink DN, Mamdani M, Blake PG, Wald R, Garg AX. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med 2011;703-704.
  62. Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, Putkonen H, Eronen M, Rasanen P. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:706-711. https://doi.org/10.4088/JCP.v69n0503
  63. Tchoukhine E, Takala P, Hakko H, Raidma M, Putkonen H, Rasanen P, Terevnikov V, Stenberg JH, Eronen M, Joffe G. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry 2011; 72:326-330. https://doi.org/10.4088/JCP.09m05283yel
  64. Benazzi F. Depression induced by orlistat (Xenical). Can J Psychiatry 2000;87.
  65. Greig SL, Keating GM. Naltrexone ER/bupropion ER: a review in obesity management. Drugs 2015;75:1269-1280. https://doi.org/10.1007/s40265-015-0427-5
  66. Dutia R, Meece K, Dighe S, Kim AJ, Wardlaw SL. β-endorphin antagonizes the effects of α-MSH on food intake and body weight. Endocrinology 2012;153:4246-4255. https://doi.org/10.1210/en.2012-1166
  67. Velazquez A, Apovian CM. Updates on obesity pharmacotherapy. Ann N Y Acad Sci 2018;1411:106-119. https://doi.org/10.1111/nyas.13542
  68. Caixas A, Albert L, Capel I, Rigla M. Naltrexone sustainedrelease/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther 2014; 8:1419-1427.
  69. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) 2010;376:595-605. https://doi.org/10.1016/S0140-6736(10)60888-4
  70. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013;21:935-943. https://doi.org/10.1002/oby.20309
  71. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19:110-120. https://doi.org/10.1038/oby.2010.147
  72. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36:4022-4029. https://doi.org/10.2337/dc13-0234
  73. Lyu X, Du J, Zhan G, Wu Y, Su H, Zhu Y, Jarskog F, Zhao M, Fan X. Naltrexone and Bupropion combination treatment for smoking cessation and weight loss in patients with schizophrenia. Front Pharmacol 2018;9:7-11. https://doi.org/10.3389/fphar.2018.00007
  74. Schmitz A, Botner B, Hund M. Bupropion with clozapine: case reports of seizure after coadministration. J Pharm Pract 2021;34:497-502. https://doi.org/10.1177/0897190020904280
  75. Castelnovo A, Zambrelli E, Canevini MP, Cavallotti S, Scarone S, D'Agostino A. Occipital seizures and visual pseudohallucinations associated with the addition of bupropion to clozapine: a case report. J Clin Psychopharmacol 2015;97-99.
  76. Yang YC, Yeh TC, Liang CS. A case of recurrent seizures: drug-drug interaction between low-dose clozapine and extended-release bupropion. Aust N Z J Psychiatry 2019;175-176.
  77. Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther 2009;16:354-364. https://doi.org/10.1097/MJT.0b013e31817fde95
  78. Pilitsi E, Farr OM, Polyzos SA, Perakakis N, Nolen-Doerr E, Papathanasiou AE, Mantzoros CS. Pharmacotherapy of obesity: available medications and drugs under investigation. Metabolism 2019;92:170-192. https://doi.org/10.1016/j.metabol.2018.10.010
  79. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 2012;20:330-342. https://doi.org/10.1038/oby.2011.330
  80. Kwak S, Youn T, Lee NY, Chung IW, Kim SH. Phentermine, phendimetrazine psychotic disorder induced by appetite suppressants, phentermine. Korean J Biol Psychiatry 2017; 24:134-141.
  81. Kim KK, Cho HJ, Kang HC, Youn BB, Lee KR. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med J 2006;47: 614-625. https://doi.org/10.3349/ymj.2006.47.5.614
  82. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95;297-308. https://doi.org/10.3945/ajcn.111.024927
  83. Narayanaswami V, Dwoskin LP. Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther 2017;170:116-147. https://doi.org/10.1016/j.pharmthera.2016.10.015
  84. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 2000;198.
  85. Evers SS, van Vliet A, van Vugt B, Scheurink AJW, van Dijk G. A low TSH profile predicts olanzapine-induced weight gain and relief by adjunctive topiramate in healthy male volunteers. Psychoneuroendocrinology 2016;66:101-110. https://doi.org/10.1016/j.psyneuen.2015.12.024
  86. Lee SH, Liu CY, Yang YY. Schizophreniform-like psychotic disorder induced by phentermine: a case report. Zhonghua Yi Xue Za Zhi (Taipei) 1998;61:44-47.
  87. Jo HS, Wang SM, Kim JJ. Recurrent psychosis after phentermine administration in a young female: a case report. Clin Psychopharmacol Neurosci 2019;17:130-213. https://doi.org/10.9758/cpn.2019.17.1.130
  88. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53:S53-S67.
  89. Mula M, Trimble MR, Lhatoo SD, Sander JWAS. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003;44:659-663. https://doi.org/10.1046/j.1528-1157.2003.05402.x
  90. Homola J, Hieber R. Combination of venlafaxine and phentermine/topiramate induced psychosis: a case report. Ment Heal Clin 2018;8:95-99. https://doi.org/10.9740/mhc.2018.03.095
  91. Ellinger LK, Ipema HJ, Stachnik JM. Efficacy of metformin and topiramate in prevention and treatment of secondgeneration antipsychotic-induced weight gain. Ann Pharmacother 2010;44:668-679. https://doi.org/10.1345/aph.1M550
  92. Upadhyay J, Polyzos SA, Perakakis N, Thakkar B, Paschou SA, Katsiki N, Underwood P, Park KH, Seufert J, Kang ES, Sternthal E, Karagiannis A, Mantzoros CS. Pharmacotherapy of type 2 diabetes: an update. Metabolism 2018; 78:13-42. https://doi.org/10.1016/j.metabol.2017.08.010
  93. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WHM. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014;38:784-793. https://doi.org/10.1038/ijo.2013.162
  94. Farr OM, Tsoukas MA, Triantafyllou G, Dincer F, Filippaios A, Ko BJ, Mantzoros CS. Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: a randomized, placebo-controlled, crossover study. Metabolism 2016;65:945-953. https://doi.org/10.1016/j.metabol.2016.03.009
  95. Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 2011;7;507-516. https://doi.org/10.1038/nrendo.2011.77
  96. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagonlike peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002;18:7-14. https://doi.org/10.1385/JMN:18:1-2:07
  97. Secher A, Jelsing J, Baquero AF, Hecksher-Sorensen J, Cowley MA, Dalboge LS, Hansen G, Grove KL, Pyke C, Raun K, Schaffer L, Tang-Christensen M, Verma S, Witgen BM, Vrang N, Bjerre Knudsen L. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014;124:4473-4488. https://doi.org/10.1172/JCI75276
  98. Son JW, Kim S. Comprehensive review of current and upcoming anti-obesity drugs. Diabetes Metab J 2020;44:802-818. https://doi.org/10.4093/dmj.2020.0258
  99. Chalmer T, Almdal TP, Vilsboll T, Knop FK. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer. Expert Opin Drug Saf 2015;14:171-180. https://doi.org/10.1517/14740338.2015.975205
  100. Monami M, Nreu B, Scatena A, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab 2017;19:1233-1241. https://doi.org/10.1111/dom.12926
  101. Kim BY, Kang SM, Kang JH, Kim KK, Kim B, Kim SJ, Kim YH, Kim JH, Kim JH, Nam GE, Park JY, Son JW, Shin HJ, Oh TJ, Lee H, Jeon EJ, Chung S, Hong YH, Kim CH. Current long-term pharmacotherapies for the management of obesity. J Obes Metab Syndr 2020;29:99-109. https://doi.org/10.7570/jomes20010
  102. Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res 2008;103:94-103. https://doi.org/10.1016/j.schres.2008.05.011
  103. Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, chjerning O, Oturai PS, Kjaer A, Nielsen J, Holst JJ, Ekstrom CT, Correll CU, Vilsboll T, Fink-Jensen A. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry 2017;74: 719-728. https://doi.org/10.1001/jamapsychiatry.2017.1220
  104. Svensson CK, Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Koyuncu K, Schjerning O, Nielsen J, Ekstrom CT, Correll CU, Vilsboll T, Fink-Jensen A. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatr Scand 2019;139:26-36. https://doi.org/10.1111/acps.12982
  105. Scaini G, Quevedo J, Velligan D, Roberts DL, Raventos H, Walss-Bass C. Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia. Eur Neuropsychopharmacol 2018;28:369-380. https://doi.org/10.1016/j.euroneuro.2018.01.004
  106. O'Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, Brett J, Cancino AP, Wilding JPH. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes, Obes Metab 2017;19:1529-1536. https://doi.org/10.1111/dom.12963
  107. Ebdrup BH, Knop FK, Ishoy PL, Rostrup E, Fagerlund B, Lublin H, Glenthoj B. Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Med 2012;10:1-7. https://doi.org/10.1186/1741-7015-10-1